Open AccessFive-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
Author(s) -
Gilberto de Castro,
Iveta Kudaba,
YiLong Wu,
Gilberto Lopes,
Dariusz M. Kowalski,
Hande Turna,
Christian Caglevic,
Li Zhang,
Bogusława Karaszewska,
К. К. Лактионов,
Vichien Srimuninnimit,
Igor Bondarenko,
Kaoru Kubota,
Rinee Mukherjee,
Jianxin Lin,
Francis Ribeiro de Souza,
Tony Mok,
Byoung Chul Cho
Publication year - 2023
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.21.02885
Subject(s) - pembrolizumab , medicine , pemetrexed , carboplatin , lung cancer , clinical endpoint , oncology , chemotherapy , hazard ratio , cancer , clinical trial , surgery , confidence interval , immunotherapy , cisplatin